https://www.selleckchem.com/products/nvp-dky709.html Lower maintenance doses likely are associated with less severe reactions, and food modification and/or adjunct therapeutics may also decrease the risk of reactions. WOIT trials are ongoing and will optimize updosing protocols and maintenance doses to improve efficacy and safety. WOIT trials are ongoing and will optimize updosing protocols and maintenance doses to improve efficacy and safety. To perform a nonsystematic review of the literature on the possible role of probiotics for food allergy (FA). Animal model and in vitro evidence suggest that the gut microbiome could protect against FA and that probiotics could be a valid instrument. There is no consistent evidence in identifying the specific species, the dosage, and the optimal duration to obtain the correct immunomodulation. Early life supplementation with specific 'missing' immunomodulatory microbes - derived from machine learning approach to birth cohort studies - might represent a novel approach to the primary prevention of multiple human atopic diseases. However, further studies are needed. Currently, there is no positive recommendation from the main scientific societies to use probiotics neither for the treatment nor for the prevention of FA. Currently, there is no positive recommendation from the main scientific societies to use probiotics neither for the treatment nor for the prevention of FA. We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma (NSCLC) and epidermal growth factor receptor (EGFR) mutation, who was treated with erlotinib, with doses adjusted by therapeutic drug monitoring (TDM). This case involved a clearance fluctuation leading to over-therapeutic drug concentrations of erlotinib and toxicity. The intra- and inter-patient variability of erlotinib, in addition to other factors such as age or variations in liver clearance, create situations that are challenging in clinical practice. During treat